Format

Send to

Choose Destination
Crit Rev Oncol Hematol. 2010 Mar;73(3):220-7. doi: 10.1016/j.critrevonc.2009.03.006. Epub 2009 Apr 14.

Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Author information

1
Department of Medical Oncology, University General Hospital of Heraklion, Greece.

Abstract

PURPOSE:

To compare efficacy and tolerability of fulvestrant with aromatase inhibitors and tamoxifen that actually represent the standard of care in hormone-sensitive breast cancer.

METHODS:

Systematic review and meta-analysis of available trials. Primary outcomes were overall survival, time to progression, clinical outcome and objective response. Secondary outcome was the tolerability profile of the drugs.

RESULTS:

Four trials were identified with 2125 eligible patients. There was no statistically significant difference between fulvestrant and other hormonal agents in terms of overall survival (pooled HR: 1.047, 95% CI: 0.688-1.592), time to progression (pooled HR: 0.994, 95% CI: 0.691-1.431), clinical benefit (pooled OR: 1.044, 95% CI: 0.828-1.315) or objective response rate (pooled OR: 0.949, 95% CI: 0.736-1.224). A higher incidence of joint disorders (pooled OR: 0.621, 95% CI: 0.424-0.909; P=0.014) was noted in patients receiving hormonal agents other than fulvestrant.

CONCLUSION:

Fulvestrant was similar to other hormonal agents with respect to efficacy measures, with good tolerability profile.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center